OptiBiotix signs license agreement with Kappa for new vascular health product

The agreement will see Lactobacillus plantarum LPLDL incorporated in new vascular health products with Kappa's proprietary K2VITAL

OptiBiotix has inked a licence agreement with Kappa Bioscience—the maker of vitamin K2, K2VITAL—that will see its Lactobacillus plantarum LPLDL in a new vascular health products. LPLDL is a brand of OptiBiotix subsidiary ProBiotix.

The agreement covers 27 countries including Russia and Singapore.

The new vascular health ingredient will combine ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL with Kappa's proprietary K2VITAL, which Kappa markets as the purest and most active form of vitamin K2.

The product is being developed to improve vascular health and is another addition to a portfolio of cardiovascular health products (cholesterol reduction, hypertension reduction) containing LPLDL.

ProBiotix's preferred development and production partner, Nutrilinea Srl. in Milan (Italy) will cover the costs of development and will be the manufacturer of the final ingredient.

Kappa and ProBiotix will commercialise the new product leveraging their existing and new distribution networks.

We are delighted to announce this deal with Kappa, which will combine two clinically proven branded ingredients into a unique formulation

Based in Norway, Kappa has developed a technology to manufacture vitamin K2 MK-7 (all-trans menaquinone-7) with the highest purity and bioavailability, allowing for more cost-effective and efficient dosing.

Dr Luis Gosalbez, Business Development Director of OptiBiotix, commented: "We are delighted to announce this deal with Kappa, which will combine two clinically proven branded ingredients into a unique formulation designed to reduce a number of independent cardiovascular risk factors."

A cardiovascular boost

OptiBiotix said a new product is being developed to optimise the complementary modes of action in both companies branded ingredients (LPLDL and K2VITAL) to reduce many independent cardiovascular risk factors.

Calcification of blood vessels reduces their elasticity leading to arterial hardening, which in turn increases cardiovascular disease morbidity and mortality.

LPLDL lowers cholesterol and blood pressure mitigating these predisposing factors while K2VITAL keeps calcium in the bones and away from the blood vessels improving vascular health.

This agreement is a strategic step to include LPLDL in a wide range of cardiovascular health supplements, and in food, dairy, and beverage products across the world

The combination of both ingredients creates a product that has the potential to reduce these risk factors and improve cardiovascular health.

This agreement is a strategic step to include LPLDL in a wide range of cardiovascular health supplements, and in food, dairy, and beverage products across the world.

For Gosalbez, this agreement increases brand recognition and value in addition to creating a demand for LPLDL as an ingredient. "This means we are able to derive revenue from both the sale of a wide range of cardiovascular health products containing LPLDL, as well as LPLDL ingredient sales," he concluded.

Companies